Argonaute RNA
PrivateLast Round
Seed
Sep 9, 2026
Total Funding Raised
$4.25M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Argonaute RNA operates in Healthcare & Life Sciences and is based in Cardiff. Its latest recorded funding round was a Seed round in July 2024.
Argonaute RNA is a biotechnology company that develops bispecific small interfering RNA (siRNA) therapeutics to silence specific genes for the treatment of cardiometabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Argonaute RNA Comparables
Compare Argonaute RNA with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Switch Therapeutics | 81% | |
| Canary Cure Therapeutics | 81% | |
| Oligon Therapeutics | 80% |
For institutional investors. Book with your work email.
Argonaute RNA Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 9, 2026 | ||||
| Seed | Jul 17, 2024 | ||||
| Seed | May 26, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Argonaute RNA Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bristol Private Equity Club | Seed |
| Fink Family Office | Seed |
| Empirical Ventures | Seed |
| Development Bank of Wales | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2026
$1.8M seed round completed.
- Apr 17, 2026
Monthly visitors increased 57% MoM.
For institutional investors. Book with your work email.
Argonaute RNA Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Argonaute RNA's valuation, stock price, and market status.
Is Argonaute RNA a public or private company?
Argonaute RNA is a private company.
What is the current stock price of Argonaute RNA?
Argonaute RNA is a private company, so its shares have no public market price. Caplight tracks Argonaute RNA's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Argonaute RNA worth (valuation)?
Valuation information for Argonaute RNA is not publicly available.
Can I buy Argonaute RNA stock?
Argonaute RNA shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Argonaute RNA's last funding round?
Argonaute RNA's most recent funding round was Seed on September 9, 2026.
Who are the main investors in Argonaute RNA?
Key investors in Argonaute RNA include Fink Family Office, Development Bank of Wales.
Will Argonaute RNA IPO soon?
No public IPO plans have been announced for Argonaute RNA.
How can I track Argonaute RNA secondary market activity?
Caplight tracks bids, offers, and trades in Argonaute RNA's shares on secondary markets.